Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs
The discussion will cover fixed-duration treatments vs continuous therapy for CLL and provide a brief overview of venetoclax-based regimens approved for 12 cycles with obinutuzumab and 24 cycles with rituximab.
EP: 1.Connections: Understanding CLL: Symptoms, Diagnosis, and What Patients Need to Know
EP: 2.Connections: CLL Diagnosis: A Patient’s Perspective and Physician Insights
EP: 3.Watchful Waiting in CLL: When Waiting Is Treating
EP: 4.LL Treatment Roadmap: Navigating First-Line Options With Your Doctor
EP: 5.CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making
Now Viewing
EP: 6.Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs
Video content above is prompted by the following:
- Can you explain what fixed-duration treatments are and how they differ from continuous therapy in CLL?
- Please briefly highlight venetoclax-based regimens, which are approved for 12 cycles in the frontline setting with obinutuzumab and 24 cycles in the relapsed/refractory setting with rituximab.?
Recent Videos
Related Content
